BridgeBio Pharma Stock Forward View - 8 Period Moving Average
| 2CL Stock | EUR 65.52 1.58 2.47% |
BridgeBio Stock outlook is based on your current time horizon. We suggest always using this module together with an analysis of BridgeBio Pharma's historical fundamentals, such as revenue growth or operating cash flow patterns.
As of 2nd of February 2026, The RSI of BridgeBio Pharma's share price is at 56. This suggests that the stock is in nutural position, most likellhy at or near its resistance level. The main idea of RSI analysis is to track how fast people are buying or selling BridgeBio Pharma, making its price go up or down. Momentum 56
Buy Extended
Oversold | Overbought |
Quarterly Revenue Growth 43.18 |
Using BridgeBio Pharma hype-based prediction, you can estimate the value of BridgeBio Pharma from the perspective of BridgeBio Pharma response to recently generated media hype and the effects of current headlines on its competitors.
The 8 Period Moving Average forecasted value of BridgeBio Pharma on the next trading day is expected to be 65.40 with a mean absolute deviation of 1.33 and the sum of the absolute errors of 70.37. BridgeBio Pharma after-hype prediction price | EUR 66.39 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
BridgeBio |
BridgeBio Pharma Additional Predictive Modules
Most predictive techniques to examine BridgeBio price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for BridgeBio using various technical indicators. When you analyze BridgeBio charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
BridgeBio Pharma 8 Period Moving Average Price Forecast For the 3rd of February
Given 90 days horizon, the 8 Period Moving Average forecasted value of BridgeBio Pharma on the next trading day is expected to be 65.40 with a mean absolute deviation of 1.33, mean absolute percentage error of 2.76, and the sum of the absolute errors of 70.37.Please note that although there have been many attempts to predict BridgeBio Stock prices using its time series forecasting, we generally do not suggest using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that BridgeBio Pharma's next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
BridgeBio Pharma Stock Forecast Pattern
| Backtest BridgeBio Pharma | BridgeBio Pharma Price Prediction | Research Analysis |
BridgeBio Pharma Forecasted Value
In the context of forecasting BridgeBio Pharma's Stock value on the next trading day, we examine the predictive performance of the model to find good statistically significant boundaries of downside and upside scenarios. BridgeBio Pharma's downside and upside margins for the forecasting period are 63.20 and 67.60, respectively. We have considered BridgeBio Pharma's daily market price to evaluate the above model's predictive performance. Remember, however, there is no scientific proof or empirical evidence that traditional linear or nonlinear forecasting models outperform artificial intelligence and frequency domain models to provide accurate forecasts consistently.
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the 8 Period Moving Average forecasting method's relative quality and the estimations of the prediction error of BridgeBio Pharma stock data series using in forecasting. Note that when a statistical model is used to represent BridgeBio Pharma stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.| AIC | Akaike Information Criteria | 104.4231 |
| Bias | Arithmetic mean of the errors | -0.8871 |
| MAD | Mean absolute deviation | 1.3278 |
| MAPE | Mean absolute percentage error | 0.0213 |
| SAE | Sum of the absolute errors | 70.3725 |
Predictive Modules for BridgeBio Pharma
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as BridgeBio Pharma. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.BridgeBio Pharma After-Hype Price Density Analysis
As far as predicting the price of BridgeBio Pharma at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in BridgeBio Pharma or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of BridgeBio Pharma, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
BridgeBio Pharma Estimiated After-Hype Price Volatility
In the context of predicting BridgeBio Pharma's stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on BridgeBio Pharma's historical news coverage. BridgeBio Pharma's after-hype downside and upside margins for the prediction period are 64.19 and 68.59, respectively. We have considered BridgeBio Pharma's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models compare with traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
BridgeBio Pharma is very steady at this time. Analysis and calculation of next after-hype price of BridgeBio Pharma is based on 3 months time horizon.
BridgeBio Pharma Stock Price Outlook Analysis
Have you ever been surprised when a price of a Company such as BridgeBio Pharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading BridgeBio Pharma backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with BridgeBio Pharma, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.38 | 2.20 | 0.87 | 0.01 | 10 Events / Month | 1 Events / Month | In about 10 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
65.52 | 66.39 | 1.33 |
|
BridgeBio Pharma Hype Timeline
BridgeBio Pharma is presently traded for 65.52on Frankfurt Exchange of Germany. The entity has historical hype elasticity of 0.87, and average elasticity to hype of competition of -0.01. BridgeBio is estimated to increase in value after the next headline, with the price projected to jump to 66.39 or above. The average volatility of media hype impact on the company the price is about 96.49%. The price rise on the next news is forecasted to be 1.33%, whereas the daily expected return is presently at 0.38%. The volatility of related hype on BridgeBio Pharma is about 6285.71%, with the expected price after the next announcement by competition of 65.51. The company reported the revenue of 353.78 M. Net Loss for the year was (495.27 M) with profit before overhead, payroll, taxes, and interest of 338.84 M. Assuming the 90 days horizon the next estimated press release will be in about 10 days. Check out Historical Fundamental Analysis of BridgeBio Pharma to cross-verify your projections.BridgeBio Pharma Related Hype Analysis
Having access to credible news sources related to BridgeBio Pharma's direct competition is more important than ever and may enhance your ability to predict BridgeBio Pharma's future price movements. Getting to know how BridgeBio Pharma's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how BridgeBio Pharma may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| CBR | CHIBA BANK | (0.05) | 2 per month | 0.68 | 0.13 | 2.21 | (1.61) | 5.31 | |
| NB9 | National Bank Holdings | 0.20 | 6 per month | 1.75 | 0.03 | 3.66 | (3.85) | 11.17 | |
| LGLG | LG Electronics | (0.40) | 9 per month | 2.66 | 0.05 | 4.65 | (4.14) | 14.81 | |
| SGM | STMicroelectronics NV | 0.25 | 7 per month | 2.09 | 0.06 | 5.82 | (3.61) | 13.11 | |
| UE1 | Universal Electronics | (0.16) | 8 per month | 0.00 | (0.02) | 5.06 | (6.20) | 21.38 | |
| XCA | CREDIT AGRICOLE | (0.05) | 5 per month | 1.41 | 0.10 | 2.03 | (2.24) | 5.34 |
Other Forecasting Options for BridgeBio Pharma
For every potential investor in BridgeBio, whether a beginner or expert, BridgeBio Pharma's price movement is the inherent factor that sparks whether it is viable to invest in it or hold it better. BridgeBio Stock price charts are filled with many 'noises.' These noises can hugely alter the decision one can make regarding investing in BridgeBio. Basic forecasting techniques help filter out the noise by identifying BridgeBio Pharma's price trends.BridgeBio Pharma Related Equities
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with BridgeBio Pharma stock to make a market-neutral strategy. Peer analysis of BridgeBio Pharma could also be used in its relative valuation, which is a method of valuing BridgeBio Pharma by comparing valuation metrics with similar companies.
| Risk & Return | Correlation |
BridgeBio Pharma Market Strength Events
Market strength indicators help investors to evaluate how BridgeBio Pharma stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading BridgeBio Pharma shares will generate the highest return on investment. By undertsting and applying BridgeBio Pharma stock market strength indicators, traders can identify BridgeBio Pharma entry and exit signals to maximize returns.
BridgeBio Pharma Risk Indicators
The analysis of BridgeBio Pharma's basic risk indicators is one of the essential steps in accurately forecasting its future price. The process involves identifying the amount of risk involved in BridgeBio Pharma's investment and either accepting that risk or mitigating it. Along with some essential techniques for forecasting bridgebio stock prices, we also provide a set of basic risk indicators that can assist in the individual investment decision or help in hedging the risk of your existing portfolios.
| Mean Deviation | 1.94 | |||
| Semi Deviation | 1.89 | |||
| Standard Deviation | 2.83 | |||
| Variance | 7.99 | |||
| Downside Variance | 5.57 | |||
| Semi Variance | 3.56 | |||
| Expected Short fall | (2.17) |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for BridgeBio Pharma
The number of cover stories for BridgeBio Pharma depends on current market conditions and BridgeBio Pharma's risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that BridgeBio Pharma is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about BridgeBio Pharma's long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Other Macroaxis Stories
Our audience includes start-ups and big corporations as well as marketing, public relation firms, and advertising agencies, including technology and finance journalists. Our platform and its news and story outlet are popular among finance students, amateur traders, self-guided investors, entrepreneurs, retirees and baby boomers, academic researchers, financial advisers, as well as professional money managers - a very diverse and influential demographic landscape united by one goal - build optimal investment portfolios
Story Categories
Currently Trending Categories
Check out Historical Fundamental Analysis of BridgeBio Pharma to cross-verify your projections. For more detail on how to invest in BridgeBio Stock please use our How to Invest in BridgeBio Pharma guide.You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.